Randomized trial · people

Tirzepatide: up to 17.5% weight loss at 52 weeks in SURMOUNT-CN

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In Chinese adults without diabetes, both the 10 mg and 15 mg arms of tirzepatide led to far more weight loss than placebo over a year, with gut side effects the most common problem.

Kind
Randomized trial
Studied in
People
Number studied
210
Published
2024
Journal
JAMA

What they tested

The team tested whether weekly tirzepatide shots work and are safe for weight loss in Chinese adults with obesity, or overweight plus a weight-related health problem.

How the study was done

A randomized, double-blind, placebo-controlled phase 3 trial at 29 centers in China in 210 adults without diabetes, who had a BMI of 28 or more, or 24 or more with at least 1 weight-related condition. For 52 weeks they got weekly injections of tirzepatide 10 mg (70 people), 15 mg (71 people) or placebo, a dummy shot (69 people), plus a lifestyle program.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking tirzepatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

At week 52, average body weight fell 13.6% in the 10 mg arm and 17.5% in the 15 mg arm, compared with 2.3% on placebo. Compared with placebo, the difference was -11.3% for 10 mg and -15.1% for 15 mg, and both differences were statistically significant. A weight loss of at least 5% was reached by 87.7% in the 10 mg arm, 85.8% in the 15 mg arm and 29.3% on placebo. Stomach and gut side effects were the most common with tirzepatide, mostly mild to moderate, and fewer than 5% of events led people to stop treatment.

What it doesn’t show

The trial ran for 52 weeks in about 70 people per group, all Chinese adults, and people with diabetes were left out. It does not show what happens after a year or in other groups.

The paper

Zhao et al. Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial. JAMA. 2024.

The compound

More studies on Tirzepatide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking tirzepatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo